PTN

Palatin科技
AMEX

实时行情|Nasdaq Last Sale

0.5895
+0.0129
+2.24%
盘后: 0.5900 +0.0005 +0.08% 19:33 08/03 EDT
开盘
0.5934
昨收
0.5766
最高
0.6000
最低
0.5780
成交量
106.69万
成交额
--
52周最高
1.133
52周最低
0.3550
市值
1.35亿
市盈率(TTM)
4.085
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PTN价格均价为2.167,最高价位3.000,最低价为1.500。

EPS

PTN 新闻

更多
Palatin Tech puts end to Vyleesi license agreement with Amag Pharma
Seeking Alpha · 07/27 12:39
Palatin Technologies Terminates its Agreement Granting AMAG Pharma Exclusive North American Reights to Market Vyleesi
Benzinga · 07/27 11:03
5 Health Care Stocks Trading With Low Price-Earnings Ratios
Genesis tops the list Continue reading...
GuruFocus.com · 07/14 17:19
Moderna's COVID-19 Vaccine And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/12 08:52
Palatin resumes enrollment in mid-stage dry eye study
Seeking Alpha - Article · 07/08 13:20
Palatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease
PR Newswire · 07/08 12:30
Palatin Technologies, Inc. Announces Reinitiation Of Enrollment Of Phase 2 Study With PL9643 For Treatment Of Dry Eye Disease
CRANBURY, N.J., July 8, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the
Benzinga · 07/08 11:33
Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders
PR Newswire · 06/29 12:30

所属板块

生物技术和医学研究
+3.60%
制药与医学研究
+2.08%

热门股票

代码
价格
涨跌幅

PTN 简况

Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.
展开

微牛提供Palatin Technologies, Inc.(AMEX-PTN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PTN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PTN股票基本功能。